Cabozantinib approved for advanced medullary thyroid cancer

被引：21
|
作者：
Traynor, Kate
机构：
来源：
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 2013年 / 70卷 / 02期
关键词：
D O I：
10.2146/news130005
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：88 / 88
页数：1
相关论文
共 50 条
  • [31] Vandetanib—a new therapeutic option in advanced medullary thyroid cancer
    Linda Koch
    Nature Reviews Endocrinology, 2012, 8 (1) : 1 - 1
  • [32] Vandetanib: A Guide to Its Use in Advanced Medullary Thyroid Cancer
    Keating, Gillian M.
    Lyseng-Williamson, Katherine A.
    Frampton, James E.
    BIODRUGS, 2012, 26 (06) : 431 - 435
  • [33] Safety of denosumab in patients with refractory differentiated thyroid cancer and advanced medullary thyroid cancer.
    Wassermann, Johanna
    Mathy, Elise
    Lescaille, Geraldine
    Slim, Marine
    Buffet, Camille
    Saie, Clotilde
    Braik-Djellas, Yasmin
    Simon, Jean-Marc
    Menegaux, Fabrice
    Tresallet, Christophe
    Chami, Linda
    Lussey-Lepoutre, Charlotte
    Herve, Genevieve
    Bernier, Marie-Odile
    Spano, Jean-Philippe
    Leenhardt, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] Primary resistance to selpercatinib in a patient with advanced medullary thyroid cancer
    Pitoia, Fabian
    Trimboli, Pierpaolo
    Abelleira, Erika
    ENDOCRINE, 2024, 86 (01) : 109 - 113
  • [35] Cabozantinib in Medullary Thyroid Carcinoma: Time to Focus the Spotlight on This Rare Disease
    Houvras, Yariv
    Wirth, Lori J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (19) : 2616 - 2618
  • [36] Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
    Kurzrock, Razelle
    Sherman, Steven I.
    Ball, Douglas W.
    Forastiere, Arlene A.
    Cohen, Roger B.
    Mehra, Ranee
    Pfister, David G.
    Cohen, Ezra E. W.
    Janisch, Linda
    Nauling, Forlisa
    Hong, David S.
    Ng, Chaan S.
    Ye, Lei
    Gagel, Robert F.
    Frye, John
    Mueller, Thomas
    Ratain, Mark J.
    Salgia, Ravi
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (19) : 2660 - 2666
  • [37] Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension
    Milling, Rikke Vilsboll
    Grimm, Daniela
    Krueger, Marcus
    Grosse, Jirka
    Kopp, Sascha
    Bauer, Johann
    Infanger, Manfred
    Wehland, Markus
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (10)
  • [38] Population pharmacokinetic/pharmacodynamic modeling of tumor growth kinetics in medullary thyroid cancer patients receiving cabozantinib
    Miles, Dale R.
    Wada, David R.
    Jumbe, Nelson L.
    Lacy, Steven A.
    Nguyen, Linh T.
    ANTI-CANCER DRUGS, 2016, 27 (04) : 328 - 341
  • [39] Cabozantinib: an orphan drug for thyroid cancer
    Viola, D.
    Cappagli, V.
    Matrone, A.
    Mazzeo, S.
    Elisei, R.
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (12): : 1469 - 1477
  • [40] Medullary thyroid cancer
    Kissin, A
    Batheja, N
    THYROID, 2000, 10 (03) : 281 - 281
12345